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Summary This study examined the autocrine production ofTGF-,B1, -,B2 and -,B3 in culture supernatants from
tumour-derived (H series, n=7; BICR series, n=5), Ha-ras-transfected (n=4) and normal (n=2) human
keratinocytes using a sandwich enzyme-linked immunosorbent assay (ELISA). Detection limits were
39.0 pg ml-1' for TGF-,ll, 78.0 pg ml-' for TGF-fl2 and 1.9 ng ml-' for TGF-,B3. Tumour-derived oral
keratinocytes predominantly produced less TGF-,B1 than normal oral epithelial cells; the expression of
endogenous TGF-,B2 was variable. In keratinocytes containing mutant Ha-ras, TGF-,B1 production was
enhanced and TGF-#2 was undetectable. TGF-,B3 mRNA was detected by reverse transcription-polymerase
chain reaction (RT-PCR) but the protein was not detected in conditioned media, most probably because of
the low detection limits of the ELISA for this isoform. Neutralisation experiments indicated that the latent
TGF-,B peptide was secreted in keratinocyte conditioned medium. Seven tumour-derived keratinocyte cell lines
(H series) and fibroblasts separated from normal (n= 1) and tumour-derived (n=2) keratinocyte cultures were
examined for their response to exogenous TGF-fil, -fl2 and -fl3. Six of seven tumour-derived keratinocyte cell
lines were inhibited by TGF-,B1 and TGF-,B2 (-,IB >-,2); one cell line was refractory to both TGF-fll and TGF-
,B2. Keratinocytes were inhibited (4 of 7), stimulated (1 of 7) or failed to respond (2 of 7) to TGF-,B3. TGF-,Bl,
-fl2 and -,B3 stimulated both normal and tumour-associated fibroblasts, but the tumour-associated fibroblasts
showed less response to the ligands than their normal counterparts following prolonged treatment with each
isoform. The results demonstrate variable autocrine production ofTGF-,B isoforms by malignant keratinocytes,
with loss of TGF-,lB generally associated with the tumour-derived phenotype and modification of endogenous
isoform production dependent on the genetic background ofthe tumour cells. Further, the variable response of
the tumour-derived keratinocytes and contiguous fibroblasts to the TGF-,B isoforms suggests that dysregulation
of TGF-,B autocrine and paracrine networks are common characteristics of squamous epithelial malignancy.
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The human TGF-fl family of growth factors (TGF-fB1, -fl2
and -fl3) are highly conserved, ubiquitous peptides that
exhibit a remarkable diversity of biological action (Roberts
and Sporn, 1991). Although members of the TGF-fl family
share many functional properties, it is now recognised that
the TGF-fl isoforms can be distinguished with respect to their
effect on cell growth (Jennings et al., 1988), their binding to
cell surface receptors (Cheifetz et al., 1990) and by the
regulation of their expression with respect to other growth
modulators (Danielpour et al., 1991). Furthermore, the
pattern of expression of the TGF-,B isoforms in embryogen-
esis (Pelton et al., 1991) and wound healing (Levine et al.,
1993) is both spatially and temporally specific, which suggests
defined functions for these proteins in tissue and cell
behaviour.
TGF-fl binds to specific high-affinity cell surface receptors
(types I, II and III) which, in epithelial cells, results in the
inhibition of c-myc gene transcription and growth arrest in
the late GI phase of the cell cycle (Coffey et al., 1988;
Pietenpol et al., 1990; Munger et al., 1992). It has been
reported that many cell lines are either refractory or partially
responsive to TGF-f11 (Fynan and Reiss, 1993) and this, in
turn, has led to the concept that loss of TGF-fl
responsiveness is a critical step in epithelial tumour
development resulting in unrestrained tumour growth. The
vast majority of studies have examined TGF-,B1 only without
reference to TGF-fl2 or TGF-f,3 and, therefore, the
possibility exists that tumour cells lose response to one
isoform but are growth inhibited/stimulated by others. We
(Prime et al., 1994) and others (B Ozanne, personal
communication) have shown that human tumour-derived
oral keratinocytes are inhibited by TGF-fll to varying
degrees, but their response to TGF-,B2 and -#3 is currently
unknown.
Almost all cell types express one or more of the TGF-,B
mRNAs (Derynck et al., 1987) and the protein is usually
secreted in the latent, inactive form. The physiological
mechanism(s) of activation of latent TGF-,B are unclear
(Lawrence, 1995) but are critical to the function of TGF-,B in
tumour development. If TGF-fB does act as an autocrine
negative regulator of cell growth (Wu et al., 1992),
modulation of the synthesis of the peptide may directly
influence tumour behaviour. Unfortunately, definitive evi-
dence for the role of TGF-/ in epithelial carcinogenesis in
vivo using sense and anti-sense constructs of TGF-fll cDNA
has been equivocal, with data to support a positive (Arteaga
et al., 1993) and negative (Wu et al., 1992) function.
Similarly, there are conflicting data demonstrating either
overexpression or loss of expression of one or more of the
TGF-fl isoforms in murine carcinomas and papillomas with a
high rate of malignant transformation (Glick et al., 1993; Cui
et al., 1994; Patamalai et al., 1994) and in a variety of human
carcinomas (Coombs et al., 1993; MacCallum et al., 1994;
Welch et al., 1990; Gorsch et al., 1992). Both tumour
heterogeneity and the complexity of the genetic changes
inherent in the neoplastic phenotype could account for these
findings. The relationship between the genetic profile of
tumour cells and autocrine ligand production clearly
warrants further investigation.
The role of TGF-,B in epithelial tumour development may
be more complex than whether malignant epithelial cells
escape ligand-induced growth inhibition or whether such cells
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produce more or less autocrine TGF-fJ. In epithelial
carcinogenesis, historically it has been assumed that the
mesenchymal stroma is a relatively passive partner during
epithelial invasion and tumour development. Recently, it has
been proposed that mesenchymal tissue actively suppresses
epithelial carcinogenesis and that when such active suppres-
sion is lost by tumour-associated mesenchyme, epithelial
tumour development is facilitated (Sporn and Roberts, 1992).
Unfortunately, there is a paucity of information concerning
the behaviour of fibroblasts associated with epithelial
malignancy and whether such cells differ from their more
normal counterparts.
In this study, we have used a number of human tumour-
derived and ras-transfected keratinocyte cell lines whose
tumorigenicity in athymic mice, together with the prevalence
of ras and p53 mutations, was known. In addition,
contiguous fibroblasts from both normal and malignant
epithelial cell cultures were available. We present evidence
that the endogenous production of the TGF-# isoforms by
human oral keratinocytes reflects not only their tumour
origin, but also the genetic background of the cell lines.
Further, we show that tumour-associated fibroblasts have a
markedly diminished response to exogenous TGF-,B com-
pared with cells from normal oral mucosa.
Materials and methods
Cell culture
Tumour-derived, human oral keratinocyte cell lines (H series,
Prime et al., 1990; BICR series, Edington et al., 1995) were
cultured in standard medium consisting of Nut-Mix
[Dulbecco's modified Eagle medium (DMEM) and Ham's
F12 medium, 1:1; Gibco] supplemented with 5% (v/v) fetal
bovine serum (FBS) plus 0.6 mg mI-' L-glutamine,
0.5 pg ml-' hydrocortisone and 10 mg ml-' cholera toxin.
The BICR series of cell lines and normal oral keratinocytes
were grown with 3T3 fibroblast support and in the absence of
cholera toxin. Contiguous fibroblasts from H357, H413 and
normal oral fibroblasts were grown in DMEM with 10% (v/
v) FBS and 0.6 mg ml-' L-glutamine. The culture of the
spontaneously immortalised human epidermal keratinocyte
cell line (HaCaT), transfected with mutated Ha-ras (1-6, 1-7,
II-3, II-4), has been described previously (Boukamp et al.,
1990). The characteristics of the keratinocyte cell lines are
summarised in Table I.
Preparation of conditioned medium
Cells were cultured in 75 cm2 tissue culture flasks until 60-
70% confluent, washed in phosphate-buffered saline (PBS)
(x 3) and incubated for a further 48 h in a humidified
atmosphere of 95% air/5% carbon dioxide at 37°C with
10 ml serum-free DMEM. Conditioned media (CM) was
pooled, centrifuged (3000g for 10 min) and 2 pg ml-'
aprotinin, leupeptin, pepstatin A, 120 pg ml-' phenylmethyl-
sulphonyl fluoride (PMSF), 100 pg ml-' bovine serum
albumin (BSA) added and the samples stored at - 70°C.
Cell numbers per flask were determined after removal of
CM.
Proteins were precipitated by adding 55 p1 of 100% (w/v)
trichloroacetic acid (TCA) to 1 ml of CM from each cell line.
After vortexing, samples were placed on ice for 30 min and
centrifuged (13 OOOg) for 10 min at 4°C. After removal ofthe
supernatant, the protein pellet was washed in 1 ml ether-
ethanol (1:1) at 4°C followed by immediate vortexing. The
sample was again centrifuged, the supernatant decanted and
the pellet lyophilised for 15 min; lyophilised samples were
stored at -70°C. Before use, the samples were solubilised
and acidified overnight at 4°C by gentle agitation in 100 pl
solubilisation buffer (4 mM hydrochloric acid, 0.15 M sodium
chloride, 0.5% BSA). Samples and standards were neutralised
using 100 pl of 0.1% (v/v) BSA, 0.15 M sodium chloride,
0.2 M Tris-HCl (pH 7.6) and 0.1% (v/v) Tween 20.
Biotin labelling of TGF-f detection antibodies
Anti-TGF-,B detecting antibodies were biotin labelled as
follows: 500 pg of each lyophilised anti-TGF-# antibody
was reconstituted in 5 pl of PBS. The addition of 192.5 pl
sodium borate buffer (0.1 M pH 8.8), 12.5 pl N hydroxy-
succinimide biotin (10 mg ml-'), and after 4 h incubation at
room temperature, 40 pl 1M ammonium chloride, gave a
biotinylated antibody concentration of 2 mg ml-'. The
antibody solution was dialysed against three changes of
PBS over 3 days and stored at -700C.
ELISA for TGF-1Il, -f2, -fl3
The TGF-,B sandwich enzyme-linked immunosorbent assay
(ELISA) used in the present study was a modification of the
technique described by Danielpour (1993). Immulon II 96-
well plates (Dynatech) were coated with 50 pl of pan-mouse
Table I Characteristics of tumour-derived (H and BICR series) keratinocyte cell lines and Ha-ras-transfected (I-6, 1-7, II-3, II-4) HaCaT
clones
Tumorigenicity in p53 mutationd
Cell linea athymic miceb Ha-ras mutationC codon (exon; base substitution)
H103 + 244 (7; G-T)
H157 +/- - 306 (8; G-A)
H314 + 176 (5; G-T) 373 (11; A-G)
H357 + 13(G-A) 61(A-G) 110 (4; G-A)
H376 - - 266 (8; G-T)
H400 - - 283 (8; C-G)
H413 - - 110 (4; G-T)
BICR-3 - - 282 (8; G-C)
BICR-6 + - 192 (6; C-.T)
BICR-10 + - Normal
BICR-31 + - 173, 174 (5; 3 bp del)
BICR-56 +- - 126- 132 (5; 21 bp del)
HaCaT - 179 (5; C-T); 281/282 (8; CC-TT)
1-6 + 179 (5; C-T); 281/282 (8; CC-TT)
I-7 + + 179 (5; C-T); 281/282 (8; CC-TT)
II-3 + + 179 (5; C-T); 281/282 (8; CC-TT)
II-4 + + 179 (5; C-T); 281/282 (8; CC-TT)
a,bPrime et al. (1990), Boukamp et al. (1990), Edington et al. (1996). +, Tumorigenic; -, non-tumorigenic; +/-, slow-growing, highly
differentiated or regressing tumour; H157 formed epidermoid cysts. cYeudall et al. (1993), Boukamp et al. (1990), Clark et al. (1993). +, Mutant
Ha-ras; -, absence of mutant Ha-ras. dYeudall et al. (1995), Lehman et al. (1993), Burns et al. (1993). BICR-10 shows no evidence of p53
expression.
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monoclonal anti-TGF-/31, -/32, -#3 capturing antibody
(100 ng per well in PBS and 0.02% sodium hydride;
Genzyme, UK) and stored initially for 2 h at room
temperature and then overnight at 4°C. After removal of
excess antibody, the wells were blocked with 300 ,ul of 1%
(w/v) BSA (in 0.15 M sodium chloride, 0.1 M Tris-HCl, pH
7.6) for 1 h at room temperature and washed with PBS-
0.05% Tween 20 (PBST). Aliquots (100 ,ul) of standards
(natural human TGF-/31; natural porcine TGF-#2; recombi-
nant human TGF-#3; R & D Systems, UK) or 50 4l of CM
samples were placed in appropriate wells and the standards
serially diluted (TGF-#I and TGF-#2, 39-1000 pg ml-',
TGF-#3, 1-60 ng ml-') in wells containing 50 pl of diluent
buffer [0.1 M Tris-HCl, 0.1% (w/v) BSA, 0.15 M sodium
chloride, 0.05% (v/v) Tween 20; pH 7.6]. The plates were
incubated, with shaking, for 1 h at room temperature
followed by washing in PBST (x 3). Biotin-conjugated
detection antibody (50 Ml) (chicken anti-porcine TGF-/31;
goat anti-porcine TGF-#2; goat anti-chicken TGF-fl3;
200 ng per well in diluent buffer; R & D Systems, UK)
was added to each well and the plates incubated, with
shaking, for 1 h at room temperature followed by washing
in PBST (x 5). Alkaline phosphatase-conjugated streptavidin
(62.5 ng per well in diluent buffer; Sigma, UK) was added to
each well and the plates incubated, with shaking, for 1 h at
room temperature. The wells were then washed in PBST
(x 5) and 1.0 M diethanolamine buffer (1 M diethanolamine,
0.5 mM magnesium chloride, pH 9.8; x 2). Phosphatase
substrate (50 tl) (1 mg ml-' p-nitrophenylphosphate in
1.0 M diethanolamine buffer) was added to each well and
the plates incubated for 30min at room temperature. The
difference in absorbance at 405 and 450 nm was measured
using a Titertek Multiscan MC96-well plate reader.
Staining controls included omission of one or more of
either the capturing antibody, the ligand, the detecting
antibody or the streptavidin. The specificity of the detecting
antibodies was examined by incubating 500 pg standard
ligand with the corresponding non-specific antibody (e.g.
TGF-,Bl with anti-TGF-/2 or anti-TGF-/3).
RNA extraction and RT-PCR
Cells were grown in DMEM plus 10% (v/v) FBS until
approximately 60-70% confluent, trypsinised and total
RNA extracted using RNeasy total RNA columns
(Qiagen). cDNA was synthesised from 1 ig total RNA
using the Superscript preamplification system (Gibco-BRL)
with oligo (dT) as a primer. The RNA-cDNA hybrid was
denatured and a fragment of the TGF-,B3 gene was amplified
using the following primers: left primer 5'-
AGATCTGGGGCGCCTCA-3', and right primer, 5'-
TGTCGCACGTGGGGTCT-3' (deduced from the pub-
lished sequence; ten Dijke et al., 1990) to give a product
of 469 bp which was confirmed by direct sequence analysis.
Thermal cycle parameters were 40 cycles of denaturation at
94°C for 1 min, annealing at 60°C for 1 min and extension
at 72°C for 1 min.
DNA synthesis assays
Assays of [3H]thymidine incorporation following treatment
of cells with TGF-,/1 have been reported previously (Game
et al., 1992); similar techniques were used to examine the
effect of TGF-/32 and TGF-RB3. In certain experiments, CM
from H357 was collected as described above, filter sterilised
and acidified by adding 1 M hydrochloric acid for 30 min
until pH 2, followed by reneutralisation in 1 M sodium
hydroxide until pH 7.2. After acidification and reneutralisa-
tion, the activated CM (2 ml per well) was added to FBS
(final serum concentration 1%) and this medium (+/
-30 Mg ml-' pan anti-TGF-,ll, -,B2, -/33 antibody preincu-
bated for 1 h at 37°C) was incubated with H400; tritiated
thymidine counts were measured after 24 h. All assays were
carried out on 3-6 separate occasions.
Results
ELISA for TGF-/3 isoforms
The sensitivities of the sandwich ELISAs for the human
TGF-/3 isoforms are shown in Figure 1. The detection limits
were 39.0 pg ml-l for TGF-/31, 78.0 pg ml-' for TGF-f2 and
1.9 ng ml-' for TGF-/33, the latter probably reflecting the
lower affinity of the anti TGF-/33 antibody. Negative staining
controls and cross-reactivity of TGF-,B isoform-specific
antibodies was consistently less than 3.5%.
Autocrine production of TGF-/3 isoforms
The production of TGF-,B1 and TGF-/32 by the normal oral
keratinocytes, the tumour-derived cell lines and the Ha-ras-
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Figure 1 Sensitivities of the sandwich ELISAs in the measure-
ment of TGF-,B1 (a), TGF-,B2 (b) and TGF-,B3 (c). The detection
limits were 39.Opgml-l for TGF-,lB, 78.Opgml-l for TGF-#2
and 1.9ngml-l for TGF-,B3.
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1transfected HaCaT clones is shown in Table II. While there
was great variability in TGF-/31 production, in general the
tumour-derived cell lines produced less TGF-,B1 (H series,
mean 242.0 pg 10-6 cells 48 h-i; BICR series, mean
352.1 pg 10-6 cells 48 h-1) than normal oral keratinocytes
(mean 587.3 pg 10-6 cells 48 h-'); exceptions were H103
(1161.9 pg 10-6 cells 48 h-1) and H357 (1808.5 pg 10-6
cells 48 h-'). By contrast, Ha-ras transfected clones (1-6, I-
7, 11-3, II-4) produced more TGF-/1 (mean, 486.1 pg 10-6
cells 48 h-') than the HaCaT cell line of origin
(203.4 pg 10-6 cells 48 h-').
TGF-#2 was detected in normal oral keratinocytes (mean,
179.0 pg 10-6 cells 48 h-1) and in 11 of 12 tumour-derived
oral cell lines. The production of TGF-/2 by the tumour-
derived keratinocytes was highly variable and, relative to
normal oral keratinocytes, TGF-,B2 values were either
increased (H376, H400, H413, BICR-6), decreased (H103,
H357, BICR-3, BICR-10, BICR-31, BICR-56) or similar
(HI57, H314). Of the Ha-ras-transfected clones, only 1-6
produced TGF-#2 (184.2 pg 10-6 cells 48 h-') and this value
was less than HaCaT cells (243.7 pg 10-6 cells 48 h-1). There
was no relationship between TGF-,Bl and TGF-/2 autocrine
production.
TGF-#3 was undetectable in all CM using the ELISA,
most probably because of the low detection levels for this
ligand in this assay. TGF-#3 mRNA was detected by RT-
PCR in both normal and tumour-derived fibroblasts and in a
representative keratinocyte cell line (H357; data not shown).
Response to TGF-/3 isoforms
The effect of TGF-,Bl, -/32 and -#3 on tumour-derived human
oral keratinocytes (H series) is shown in Figure 2. Six of
seven cell lines were inhibited by TGF-/l and TGF-,B2
(0.1 ng ml-1 for 24 h), although the effect of TGF-,B2 was
consistently less marked than TGF-,B1 (exception H413);
H314 was refractory to both TGF-/3l and TGF-#2. The
response ofthe keratinocyte cell lines to TGF-,B3 was variable
with evidence of inhibition (less than the effect of TGF-#2;
H357, H376, H400, H413), stimulation (H157) or complete
loss of response (H103, H314).
Figure 3 shows the effect of the TGF-# isoforms on
fibroblasts from normal oral mucosa and fibroblasts isolated
from cultures of H357 and H413. Cells were stimulated by
0.1 ng ml-' TGF-,B1, -/32 and -,B3 for 24 h. Fibroblasts
TGF-fi production and responses in keratinocytes
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derived from H357 and H413 (passage 22-24) showed less
response to the TGF-# isoforms compared with cells from
normal oral mucosa (passage 5-6) after protracted (48 h)
ligand treatment. This trend was repeated when normal oral
fibroblasts were examined at later culture passages (>20) and
in tumour-derived fibroblasts from H357 and H413 examined
at early culture passage (< 10), suggesting a stable phenotypic
trait.
Neutralisation of TGF-13
The inhibitory effect of neutralising autocrine TGF-# activity
on keratinocyte growth in vitro is shown in Figure 4. H400
was markedly inhibited by the addition of 1 ng ml-'
exogenous TGF-#l (A vs B) and CM from H357 (A vs F).
The effect was more marked when the CM was activated (F
vs D). The inclusion of a pan anti-TGF-,13, -,B2, -#3 antibody
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Figure 2 Tritiated thymidine incorporation per cell in cultures of
human tumour-derived oral keratinocytes following incubation
with exogenous TGF-,B1 (_), TGF-,B2 (E) or TGF-,B3 (M)
(1 ngml-1) for 24h. Results are expressed as a percentage of
untreated controls. Data points are the means oftriplicate wells at
two separate culture passages; bars indicate standard deviations.
Cells were assayed at passages <25. The basal level of thymidine
incorporation was 17.4-48.5 x 103 c.p.m. for 2h at 37°C.
Table H Autocrine productiona of TGF-JJ isoforms by normal and tumour-derived human oral keratinocytes (H and
BICR series) and Ha-ras-transfected HaCaT clones (I-6, 1-7, 11-3, II-4)
TGF-,BI TGF-/32
Cell line (pg106 cells 48h-) (pg 1J6 cells 48h-')
H103 1161.9 (843.2-1479.5) 142.3 (64.9-312.3)
H157 67.8 (34.3 -96.0) 162.9 (102.7-248.0)
H314 443.3 (371.7-553.9) 229.4 (175.4-276.9)
H357 1808.5 (1454.6-2080.0) ND
H376 504.0 (328.0-720.0) 440.0 (360.0-560.0)
H400 101.5 (97.1-125.0) 395.0 (250.0-529.4)
H413 93.4 (65.2-147.7) 264.9 (195.7-369.2)
BICR-3 362.5 (326.5-408.2) 56.2 (32.7-81.6)
BICR-6 400.5 (373.5-423.4) 466.9 (311.3-560.3)
BICR-10 209.5 (161.4-259.7) 50.2 (46.8-51.9)
BICR-31 448.0 (352.0-576.0) 46.9 (41.6-51.2)
BICR-56 340.1 (326.5-367.4) 70.8 (65.3-73.5)
HaCaT 203.4 (177.9-218.7) 243.7 (186.7-310.2)
1-6 457.5 (365.2-564.7) 184.2 (112.9-208.7)
1-7 535.1 (315.8-768.0) ND
11-3 556.4 (436.4-692.3) ND
11-4 395.3 (365.2-564.7) ND
Normal oral keratinocytes 1 553.9 (481.3-700.1) 175.7 (151.3-209.9)
Normal oral keratinocytes 2 620.7 (477.6-752.5) 182.2 (164.9-202.4)
aMean values with range in parenthesis. Samples of conditioned medium were assayed in triplicate in two separate
experiments. ND, not detectable.
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Figure 3 Tritiated thymidine incorporation per cell in cultures of
human fibroblasts separated from normal and tumour-derived
(H357, H413) oral keratinocytes. Cells were incubated with
exogenous TGF-,B1, TGF-,B2 or TGF-,B3 (1 ngml-') for 24
(_) and 48 (I ) h. Results are expressed as a percentage of
untreated controls. Data points are the mean of triplicate wells at
two separate culture passages; bars indicate standard deviations.
Fibroblasts from cultures of normal and tumour-derived oral
keratinocytes were assayed at passages 5-6 and 22-24
respectively. The basal level of thymidine incorporation was
0.429-2.39x 103 c.p.m. for 2h at 37°C.
in either activated CM from H357 (D vs E) or to medium
containing exogenous TGF-#1 (B vs C) increased thymidine
incorporation in H400. Addition of the pan TGF-,B antibody
to unactivated CM did not change thymidine incorporation
in H400 (F vs G).
Discussion
This study examined the autocrine production of TGF-1
isoforms in keratinocyte cell lines derived from a broad
spectrum of human oral squamous cell carcinomas and in
Ha-ras-transfected clones of the spontaneously immortalised
epidermal HaCaT cell line. The sandwich ELISA used in the
present study facilitated the separate measurement of TGF-
p1, -,B2 and -,B3 in the same culture supernatant and, thereby,
extended previous work by our group in which an assay of
competitive inhibition of ligand binding was used to quantify
total TGF-,B autocrine production (Game et al., 1992; Prime
et al., 1994). The sensitivity and specificity of the sandwich
ELISA in this study compared favourably with that described
previously for TGF-,il (Danielpour, 1993).
Several tumour types are known to secrete active TGF-,B
(Arteaga et al., 1990; Takiuchi et al., 1992). The results of the
present study indicate that TGF-,B was secreted predomi-
nantly as the latent peptide. For example, the addition of a
pan TGF-,B antibody to unactivated CM had no effect on
thymidine incorporation in a target cell line (Figure 4, F vs
G) and acidification and reneutralisation of CM was
necessary for a marked decrease in thymidine incorporation
(Figure 4, D vs F). Untreated CM also inhibited thymidine
incorporation (Figure 4, A vs F), but whether this was
indicative of media depletion and/or the presence of other
inhibitory factors is currently unknown. The low level of
thymidine incorporation in these studies may have been due
to the relatively weak effects of autocrine TGF-,B on cellular
proliferation or to the loss of neutralising antibody activity
during the course of the experiment. While the tumour cells
in the present study appeared not to activate endogenous
latent TGF-# in vitro, it seems likely that the latent peptide
would be activated in vivo in view of the likely presence of
plasmin, the effect of cell-cell interactions and the acidic
microenvironment of the tumour milieu (Lawrence, 1995).
Autocrine-negative regulation of human breast and colon
carcinoma cells by TGF-,lB has been reported previously
(Arteaga et al., 1990; Hafez et al., 1990).
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Figure 4 Tritiated thymidine incorporation per well in H400 cells
cultured for 24h in DMEM containing 1% (v/v) FBS (A), 1% v/v
FBS with 1 ngml-I TGF-PfI plus anti-TGF-fJ1, -,B2, -,B3 antibody
(30jugml-1; C). Similarly, H400 cells were cultured for 24h in
CM from H357 supplemented with FBS (1%, v/v, final
concentration, serum added after activation of medium).
Experiments were performed using activated media (acidification
with 1 M HCl until pH2 followed reneutralisation with 1 M
sodium hydroxide until pH 7.2; D), activated media plus pan-
TGF-,B antibody (E), non-activated media (F) and non-activated
media plus pan-TGF-,B antibody (G). Data points are the means
of triplicate wells on two separate occasions; bars indicate
standard deviations.
The expression of TGF-,B1 by the tumour-derived human
oral keratinocytes in this study was variable and may reflect a
normal variation about a mean. However, 10 of 12 tumour-
derived oral keratinocyte cell lines (exceptions H103 and
H357) produced less TGF-,B1 than normal oral keratinocytes
and these findings were evident using two series of cell lines
established in different laboratories (H and BICR series). It is
unclear as to why H103 produced high levels of TGF-#1
protein but H357 contained a genetic anomaly that could
have contributed to the high protein production (discussed
below). The expression of TGF-f2 was even more variable
than TGF-f1. Six of twelve tumour-derived cell lines (H and
BICR series) produced less TGF-,B2 than normal oral
keratinocytes and only in four cell lines was the value
increased. There have been a number of reports of both
increased (Gorsch et al., 1992) and reduced (Coombs et al.,
1993) TGF-# expression in epithelial neoplasia and such
conflicting data most probably reflect the cellular origin of
the tumour. In skin, loss ofTGF-,B1 and/or TGF-,B2 has been
demonstrated immunocytochemically in squamous cell
carcinomas and in murine papillomas with a high rate of
malignant conversion (Glick et al., 1994; Cui et al., 1994).
Whether the loss of TGF-/31/-#2 has functional significance
for epithelial tumour development in vivo, however, remains
unclear. Anti-sense constructs of TGF-,B1 cDNA promote
tumorigenic conversion of human colon carcinoma cells (Wu
et al., 1992) and targeted deletion of the TGF-,B1 gene in vivo
leads to progression of initiated murine keratinocytes to
squamous cell carcinomas (Glick et al., 1994). In the present
study, there was no clear relationship between TGF-,B1/-,B2
autocrine production and the tumorigenicity of the cell lines
in athymic mice. Interestingly, tumorigenic cell lines (H103,
H314, H357, BICR-10, BICR-31, BICR-56) tended to
produce high levels of TGF-f31 relative to TGF-/2 and,
conversely, non-tumorigenic cell lines (H376, H400, H413)
produced the same or less TGF-,B1 relative to TGF-,B2. The
significance of these observations is unknown and it is
cautionary to note that exceptions were evident (H157,
BICR-3, BICR-6).
The autocrine production of the TGF-,B isoforms was
examined in the context of the genetic background of the cell
lines. Cells that overexpressed mutant Ha-ras (1-7, 11-3, II-4;
Boukamp et al., 1990) produced more than twice the amount
of TGF-,B1 and an absence of TGF-#2 compared with the
HaCaT cell line of origin. In 1-6 cells, where mutant Ha-ras
was present but not overexpressed (Boukamp et al., 1990),
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TGF-,B1 production was increased and TGF-,B2 was
decreased relative to HaCaT cells. These findings are
consistent with the expression of TGF-fJ1 mRNA in Ha-
ras-transfected clones of HaCaT cells, but contrast with our
previous data where loss ofTGF-/ protein was noted by 11-3
and 11-4 cells (Game et al., 1992). In the present study,
however, we measured immunogenic TGF-,B isoforms rather
than total TGF-,B concentrated by ultrafiltration (Game et
al., 1992). The data obtained for the Ha-ras-transfected
HaCaT clones in the present study were supported by the
findings in the only tumour-derived cell line containing
mutant Ha-ras where TGF-#1 was markedly enhanced and
TGF-fl2 undetectable in H357; the level of Ha-ras expression
in this cell line is currently unknown. Transcriptional
activation of the TGF-,B1 gene by the Ha-ras oncogene has
been demonstrated previously (Geiser et al., 1991) but the
present report is the first to suggest down-regulation of TGF-
f2 expression by mutant Ha-ras.
In the present study, the majority of the H series of
tumour-derived cell lines were inhibited by TGF-fi1, TGF-f,2
and TGF-#3. In general, cells that responded to TGF-,B1
were also inhibited by TGF-f,2, albeit to a lesser extent. The
cellular response to TGF-#3 was variable with evidence of
inhibition (H357, H376, H400, H413), stimulation (H517) or
a lack of response (H103, H314). While such variability may
reflect the pattern of expression of cell surface receptors by
individual cell lines and/or the cell culture conditions, the
results show that a loss of response to one isoform, for
example in H314, is invariably associated with a loss of
response to the other isoforms ofTGF-f. The data also argue
against the generally held concept that loss of TGF-f,
responsiveness is a ubiquitous feature of malignant epithelial
cell lines (Fynan and Reiss, 1993).
In general, TGF-f is growth stimulatory for a variety of
mesenchymal cells including fibroblasts, chondrocytes and
osteoblasts (Roberts and Sporn, 1991). In the present study,
fibroblasts from normal oral mucosa were stimulated by
TGF-f,l, -f2 and -#3, an effect that was more marked after
48 h than 24 h of ligand treatment. By contrast, fibroblasts
derived from early cultures of tumour-derived keratinocytes
(H357 and H413) lost their stimulatory response to
exogenous TGF-,Bl, -#2 and -fl3 such that the cells were
less responsive after 48 h compared with 24 h of ligand
treatment. Schor et al. (1994) have shown that fibroblasts
associated with tumour-derived keratinocytes are functionally
abnormal, data that support our findings. Interestingly,
tumorigenicity of ras-transfected primary murine keratino-
cytes can be suppressed by the addition of normal dermal
fibroblasts (Dotto et al., 1988), an effect thought to be
mediated by TGF-,B3 (Missero et al., 1991). It may be,
therefore, that aberrant fibroblasts associated with epithelial
tumour development provide a selective growth advantage
for tumour cells in vivo by failing to produce normal levels of
TGF-f3. It was not possible to test this hypothesis because of
difficulties in the collection of CM from fibroblasts (loss of
cell adhesion and viability occurred in serum-free media) and
the lack of sensitivity of the TGF-f3 ELISA. Alternative
methods of quantifying TGF-fl3 expression, such as RT-
PCR, were also explored but were not without difficulty.
RT-PCR is at best semi-quantitative and Colletta et al.
(1990) have shown that TGF-,B regulation occurs post-
transcriptionally suggesting that protein production should
be measured directly rather than by mRNA alone. Never-
theless, we demonstrate TGF-#3 autocrine production by
both normal and tumour-derived fibroblast cell lines using
RT-PCR. The study of mesenchymal control of epithelial
tumour development via TGF-# warrants further investiga-
tion in view of the recent work of Shah et al. (1995)
demonstrating isoform-specific effects of TGF-,B in wound
healing.
In conclusion, this study demonstrates variable autocrine
production of TGF-fI and -#2 by human tumour-derived
and Ha-ras-transfected keratinocytes. The peptide was
secreted in the latent form. Decreased expression of TGF-
P1 was a general characteristic of the tumour-derived cell
lines and overexpression of TGF-fB1 together with loss of
expression of TGF-,B2 was a feature of cells containing
mutant Ha-ras. Keratinocytes were predominantly growth
inhibited by TGF-#l, -fl2 and -,B3, but certain cell lines had a
diminished response to the ligands, or were either refractory
or stimulated by specific TGF-# isoforms. Further, tumour-
associated fibroblasts partially lost a growth-stimulatory
response to the TGF-,B isoforms. The results demonstrate a
marked dysregulation of autocrine and paracrine TGF-#
networks in squamous epithelial malignancy.
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